Skip to main content
PAVSNasdaqinactive

Paranovus Entertainment Technology Ltd.

·New York, NY, United States·CEO: Ms. Xiaoyue Zhang

PAVS evidence brief

What we can confirm

No verified snapshot fields are available yet.

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

Watch the next source-backed data update.
BioSniper AIPage evidence connected

Prepared research question

What matters most for PAVS—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

Market Cap

$7.5M

Cash Runway

Lead Asset

Next Catalyst

Financial data as of Sep 30, 2025.

Run Paranovus Entertainment Technology Ltd. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available Paranovus Entertainment Technology Ltd. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Financials

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

1

Total value held

$2

HolderSharesValue
morgan stanley1$2

Short Interest

as of Apr 24, 2026
% of float
7.3%
Days to cover
0.0
Shares short
69,101
Daily short volume
-

Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →

PAVS short interest

Frequently asked questions

Who is the CEO of Paranovus Entertainment Technology Ltd.?

Ms. Xiaoyue Zhang is the chief executive officer of Paranovus Entertainment Technology Ltd. (PAVS).

Where is Paranovus Entertainment Technology Ltd. headquartered?

Paranovus Entertainment Technology Ltd. (PAVS) is headquartered in New York, NY, United States.

925 companies232,681 SEC filings21,419 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.